History of Tofacitinib

  • Tofacitinib (xeljanz) falls under the janus kinase (JAK) inhibitors, discovered and developed by the National Institutes of Health and Pfizer. It is a kind of small molecule, rather than a biologic. 
  • The potential significance of JAK3 inhibitor was foremost originated in the laboratory of John O'Shea, an immunologist at the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH).
  • In the year of 1994, the NIH approached Pfizer for establishing a public private partnership in order to assess and reach market experimental compounds.
  • Initially, Pfizer has declined the partnership, but around a couple of years later Pfizer agreed for the partnership, following the removal of an National Institutes of Health policy mentioning that the price of market of a product resulting from the such partnership would require in order to be commensurate with the investment of the public taxpayer revenue and the health as well as safety requires of the public.
  • Pfizer worked together with the laboratory of O'Shea in order to define the structure as well as function of the JAK3 and its receptors, and then managed the discovery of medication, preclinical development, and tofacitinib's clinical development in-house.
  • The medication was coded as CP-690,550 while in development. Its genuine rINN was tasocitinib, but that was overruled while on the process approval of INN as being not optimally differentiable from certain other existing INNs, so the name "tofacitinib" took place and established the INN.
  • In the month of November, 2012, tofacitinib was approved by the US Food and Drug Administration in order to treat Rheumatoid Arthritis. 
  • A 2014 study showed that tofacitinib treatment was able to convert white fat tissues into more metabolically active brown fat, suggesting it may have potential obesity applications in the treatment of obesity.
  • In the month of November, 2012, tofacitinib got the approval by US FDA in order to treat adult patients with moderate/severe active RA and have had an inconsiderable response to, or who are not tolerant of, methotrexate.
  • The US FDA approved only the tofacitinib 5 mg, twice in a day dose on the grounds that a greater dose was unconsidered to have an adequate risk to the benefit ratio.
  • The tofacitinib price in india is around 66,344 INR for a supply of a bottle of 60 tablets, depending on the pharmacy/wholesaler you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy tofacitinib. 


Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found ...
Read more

Lenvatinib Medication Guide

Lenvatinib is recommended for treating patients with locally recurrent, progressive, metastatic, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), together with everolimus for advanced renal cell carcinoma and for hepatocellular carcinoma.  Here are a few important points for patients before taking Lenvatinib:- Female patients who are able to become pregnant must use an effective method of birth control while on the treatment with lenvatinib and for at least 2 weeks after its last dose. Discuss with your doctor about the birth control methods you can use during this time. Lenvatinib is taken at the same time each and every day. If a patient misses any dose, and it cannot be consumed within 12 hours, then that dose must be skipped and the next dose should be consumed at the usual time of administration. The recommended dose is lenvatinib 24 mg (two lenvatinib 10 mg capsules and one lenvatinib 4 mg capsule) orally, taken once in a day, either with or...
Read more

Difference Between Multiple Myeloma And Leukemia

Image
What is multiple myeloma:  This is also known as plasma cell myeloma or Kahler's disease. It is a cancer in plasma cells that typically produce antibodies. When there is only one tumor present it is called as plasmacytoma and when more than one then called as multiple myeloma. The main cause of myeloma is unknown but the major risk factors are obesity,  inheritance chemicals, radiation, etc. With the effect of cancer, there is an abnormality in plasma cells that produces abnormal antibodies that can cause kidney problems. At the initial stage, there is no sign and symptoms but with the advancement of time bone pain, bleeding, anemia and frequent infections are the common symptoms. Multiple myeloma is diagnosed with the help of blood or urine tests or bone marrow biopsy. And the medication of multiple myeloma includes: Chemotherapy- There are several drugs that are used in the treatment of multiple myeloma such as doxorubicin, etoposide, cisplatin, cyclophosphami...
Read more